Clinical Trial: Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden

U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06867536) titled 'Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden' on Feb. 11.

Brief Summary: Glofitamab has shown efficacy and safety in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and has been approved for marketing in China. However, in patients with baseline high tumor burden, the complete response (CR) rate is relatively lower compared with patients without (Dickinson, et al. 2022). There is still a need to improve the efficacy of glofitamab in patients with high tumor burden. Previous studies have shown ...